Cytokinetics, Inc. (CYTK) Tops Q1 EPS by 1c

Cytokinetics, Inc. (NASDAQ: CYTK) reported Q1 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.82 million versus the consensus estimate of $1.06 million.

For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• L3Harris names Sam Mehta CEO after Kubasik exits over conduct issues
• Evaxion adds brain cancer vaccine program, drops EVX-03